CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients (Q2867196)

From EU Knowledge Graph
Revision as of 10:29, 13 September 2021 by DG Regio (talk | contribs) (‎Removed claim: co-financing rate (P837): 76.0 percent, Removing co-finance rate from projects in portugal)
Jump to navigation Jump to search
Project Q2867196 in Portugal
Language Label Description Also known as
English
CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients
Project Q2867196 in Portugal

    Statements

    0 references
    492,223.04 Euro
    0 references
    1 April 2020
    0 references
    31 December 2020
    0 references
    LIMM THERAPEUTICS, SOCIEDADE ANÓNIMA
    0 references
    0 references

    40°21'55.76"N, 8°39'29.95"W
    0 references
    O projeto apresentado pela LiMM Therapeutics pretende avaliar a possibilidade de desenvolvimento de NRIL01 (reprogramadores neuronais de linfócitos inatos) na presença de SARS-CoV-2, contribuindo desta forma para minimizar as patologias renais como consequência da infeção com este vírus. (Portuguese)
    0 references
    The project presented by LIMM Therapeutics aims to evaluate the possibility of developing NRIL01 (neurnal reprogrammers of innate lymphocytes) in the presence of SARS-CoV-2, thus contributing to minimising renal pathologies as a consequence of infection with this virus. (English)
    7 July 2021
    0 references
    Cantanhede
    0 references

    Identifiers

    CENTRO-01-02B7-FEDER-069917
    0 references